Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

Bone Fracture Clinical Trial

Official title:

Sustained Acoustic Medicine (SAM) for Symptomatic Treatment of Pain Related to Bone Fracture

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05883241
• Other study ID #: BF-01-2023
• Status: Recruiting
• Phase: Phase 1
• Start date: June 1, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2023
• Source: ZetrOZ, Inc.
• Contact: George K. Lewis, Ph.D.
• Phone: 8882029831
• Email: george[@]zetroz.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the ability of long-duration low-intensity therapeutic ultrasound (LITUS) to alleviate bone-fracture related pain over a 12-week period.

The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from bone-fracture pain.

Secondary objectives are to assess the ability of LITUS to improve patients return to work time.

Description:

This is a 12-week study to clinically evaluate the effectiveness of the Sustained Acoustic Medicine (SAM) device combined with diclofenac on symptoms of patients suffering from pain related to a bone fracture(s). The class-II device, sam®, has been FDA-cleared for home use. On the first day of the study, baseline data will be collected as patients report pain score before treatment. During the following 12 weeks, patients will self-apply their treatment for the 4 hours daily. Each day of the study, pain scores will be recorded immediately before application of SAM device, during treatment, and at the completion of treatment.

Over 90 subjects will be recruited from neighboring communities to the study site(s). The study is designed to reach a diverse target patient population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Have physician-diagnosed bone fracture

• Are between 18-80 years of age

• Report a pain score between 3-7 (range: 0-10) prior to enrolment

• Report that pain from fracture negatively affects quality of life

• Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved treatment provided to the subject at the initiation of the study

• Are deemed appropriate by their physician or by the study site physician to participate.

• Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.

• Not use or initiate opioid and/or non-opioid analgesic medications.

• Be willing to discontinue any other interventional treatment modalities on the affected area during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).

Exclusion Criteria:

• Cannot successfully demonstrate the ability to put on and take off the device.

• Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.

• Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.

• Is pregnant.

• Is a prisoner.

• Is non-ambulatory (unable to walk).

• Has a pacemaker.

• Has a malignancy in the treatment area.

• Has an active infection, open sores, or wounds in the treatment area.

• Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.

• Has a known neuropathy (disease of the brain or spinal nerves).

• Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).

• Are currently taking steroids.

Related Conditions & MeSH terms

• Bone Fracture
• Fractures, Bone

Intervention

Device:
• Sustained Acoustic Device with 2.5% Diclofenac Patch
Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3-megahertz (MHz) frequency and 0.132 Watts/cm^2 with 2.5% Diclofenac patches.

Drug:
• 2.5% Diclofenac Patches
Topical pain relief-gel worn during treatment via SAM patch.

Locations

Country	Name	City	State
United States	National Sports Medicine Institute	Lansdowne Town Center	Virginia
United States	ZetrOZ Systems LLC	Trumbull	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
ZetrOZ, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pain Units on a Scale (0-10) 0 Being Least, 10 Being Worst Pain from Baseline	Change in the self-described pain units on a scale by patient at baseline and post-treatment.	Through study completion, average of 12 weeks.

External Links

•   Class II Medical Device